Patents Assigned to Vaccinex, Inc.
  • USE OF SEMAPHORIN-4D ANTIBODIES IN COMBINATION WITH AN IMMUNE MODULATING THERAPY TO INHIBIT TUMOR GROWTH AND METASTASIS
    Publication number: 20250032609
    Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
    Type: Application
    Filed: July 18, 2024
    Publication date: January 30, 2025
    Applicant: Vaccinex, Inc.
    Inventors: Elizabeth E. Evans, Ernest S. Smith, Maurice Zauderer
  • Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
    Patent number: 12201719
    Abstract: Disclosed are compositions and methods comprising the administration of pulsed dendritic cells and an immunoregulator molecule inhibitor for the treatment of cancer.
    Type: Grant
    Filed: April 27, 2023
    Date of Patent: January 21, 2025
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc. (A Florida Non-Profit Corporation), VACCINEX, INC.
    Inventors: Brian Czerniecki, Krithika N. Kodumudi, Elizabeth Evans
  • HUMAN ANTI-SEMAPHORIN 4D ANTIBODY
    Publication number: 20240309091
    Abstract: Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.
    Type: Application
    Filed: May 3, 2024
    Publication date: September 19, 2024
    Applicant: VACCINEX, INC.
    Inventors: Ernest S. SMITH, Angelica CORNELISON, Maria SCRIVENS, Mark PARIS, Maurice ZAUDERER
  • Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis
    Patent number: 12070500
    Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: August 27, 2024
    Assignee: VACCINEX, INC.
    Inventors: Elizabeth E. Evans, Ernest S. Smith, Maurice Zauderer
  • Anti-CD100 antibodies and methods for using the same
    Patent number: 12006364
    Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: June 11, 2024
    Assignee: VACCINEX, INC.
    Inventors: Ernest S. Smith, Terrence Lee Fisher
  • Human anti-semaphorin 4D antibody
    Patent number: 12006365
    Abstract: Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.
    Type: Grant
    Filed: July 19, 2022
    Date of Patent: June 11, 2024
    Assignee: VACCINEX, INC.
    Inventors: Ernest S. Smith, Angelica Cornelison, Maria Scrivens, Mark Paris, Maurice Zauderer
  • Anti-CCR8 Antibodies and Uses Thereof
    Publication number: 20240182588
    Abstract: The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.
    Type: Application
    Filed: November 17, 2023
    Publication date: June 6, 2024
    Applicant: Vaccinex, Inc.
    Inventors: Pamela M. HOLLAND, Andrew LAKE, Austin DULAK, Ernest Smith, Maria Scrivens, Caroline Harvey, Renee Kirk, Leslie Balch, Sonia DAS, Christopher Converse Wells
  • Anti-CXCL13 antibodies and methods of using the same
    Patent number: 11981730
    Abstract: Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: May 14, 2024
    Assignee: Vaccinex, Inc.
    Inventors: Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith
  • Integral membrane protein display on poxvirus extracellular enveloped virions
    Patent number: 11976383
    Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation on poxvirus extracellular virions and methods for screening, selecting, and identifying antibodies or antibody-like molecules that bind to a target IMP of interest.
    Type: Grant
    Filed: May 5, 2021
    Date of Patent: May 7, 2024
    Assignee: VACCINEX, INC.
    Inventors: Ernest S. Smith, Maria G. M. Scrivens, Loretta Mueller, Shuying Shi, Leslie A. Balch
  • Anti-CCR8 antibodies and uses thereof
    Patent number: 11859000
    Abstract: The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: January 2, 2024
    Assignee: Vaccinex Inc.
    Inventors: Pamela M. Holland, Andrew Lake, Austin Dulak, Ernest Smith, Maria Scrivens, Caroline Harvey, Renee Kirk, Leslie Balch, Sonia G. Das, Christopher Converse Wells
  • Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
    Patent number: 11660330
    Abstract: Disclosed are compositions and methods comprising the administration of pulsed dendritic cells and an immunoregulator molecule inhibitor for the treatment of cancer.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: May 30, 2023
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., VACCINEX, INC.
    Inventors: Brian Czerniecki, Krithika N. Kodumudi, Elizabeth Evans
  • Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
    Patent number: 11597765
    Abstract: Provided herein are methods for alleviating symptoms in a subject having Rett syndrome, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D).
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: March 7, 2023
    Assignees: VACCINEX, INC., The Sydney Children's Hospital Network
    Inventors: Yilin Mao, Wendy Gold, Elizabeth E. Evans, Maurice Zauderer
  • Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent
    Patent number: 11572408
    Abstract: This disclosure provides a method for inhibiting, delaying, or reducing malignant cell growth in a subject with cancer, comprising administering to the subject a combination therapy comprising an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of an epigenetic modulating agent, e.g., a histone deacetylase (HDAC) inhibitor (HDACi) a DNA methyltransferase (DNMT) inhibitor (DNMTi), or any combination thereof. The disclosure further provides a pharmaceutical composition comprising the combination therapy.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: February 7, 2023
    Assignee: Vaccinex, Inc.
    Inventors: Elizabeth Evans, Ernest Smith, Maurice Zauderer
  • Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
    Patent number: 11534488
    Abstract: Provided herein are methods for decreasing blood-brain barrier permeability in a subject with a neuroinflammatory disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its high affinity Plexin-B1 receptor.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: December 27, 2022
    Assignee: VACCINEX, INC.
    Inventors: Ernest S. Smith, Maurice Zauderer
  • Human anti-semaphorin 4D antibody
    Patent number: 11427634
    Abstract: Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: August 30, 2022
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Angelica Cornelison, Maria G. M. Scrivens, Mark Paris, Maurice Zauderer
  • Anti-CD100 antibodies and methods for using the same
    Patent number: 11274149
    Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: March 15, 2022
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Terrence Lee Fisher
  • ANTI-CCR8 ANTIBODIES AND USES THEREOF
    Publication number: 20210238292
    Abstract: The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.
    Type: Application
    Filed: January 6, 2021
    Publication date: August 5, 2021
    Applicant: Vaccinex, Inc.
    Inventors: Pamela M. HOLLAND, Andrew LAKE, Austin DULAK, Ernest SMITH, Maria SCRIVENS, Carrie HARVEY, Renee KIRK, Leslie BALCH, Sonia G. DAS, Christopher Converse WELLS
  • Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases
    Patent number: 11078295
    Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: August 3, 2021
    Assignee: Vaccinex, Inc.
    Inventors: Elizabeth Evans, Ernest S. Smith, Maurice Zauderer
  • TREATMENT OF CANCER WITH A SEMAPHORIN-4D ANTIBODY IN COMBINATION WITH AN EPIGENETIC MODULATING AGENT
    Publication number: 20210179708
    Abstract: This disclosure provides a method for inhibiting, delaying, or reducing malignant cell growth in a subject with cancer, comprising administering to the subject a combination therapy comprising an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of an epigenetic modulating agent, e.g., a histone deacetylase (HDAC) inhibitor (HDACi) a DNA methyltransferase (DNMT) inhibitor (DNMTi), or any combination thereof. The disclosure further provides a pharmaceutical composition comprising the combination therapy.
    Type: Application
    Filed: March 14, 2018
    Publication date: June 17, 2021
    Applicant: Vaccinex, Inc.
    Inventors: Elizabeth EVANS, Ernest SMITH, Maurice ZAUDERER
  • COMBINED INHIBITION OF SEMAPHORIN-4D AND TGF-BETA AND COMPOSITIONS THEREFOR
    Publication number: 20210032322
    Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of plexin-B1, plexin-B2, and/or CD72-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of antibody or antigen-binding fragment thereof that inhibits TGF?, and, optionally, at least one other immune modulating therapy.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 4, 2021
    Applicant: Vaccinex, Inc.
    Inventors: Elizabeth E. Evans, Holm Bussler